Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + carboplatin
- Development stage
- Phase 3
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Gemcitabine + carboplatin is a combination chemotherapy regimen used primarily to treat various cancers including advanced ovarian cancer, non-small cell lung cancer (NSCLC), and bladder cancer. Both drugs are administered intravenously in cycles of 21 days. Gemcitabine is a nucleoside analog antimetabolite that inhibits DNA synthesis by blocking the progression of cells through the G1/S-phase boundary and interfering with ribonucleotide reductase and DNA polymerization. Carboplatin is a platinum-based compound that causes crosslinking of DNA strands, leading to apoptosis in rapidly dividing cells such as cancer cells. The combination exploits different mechanisms to maximize cytotoxicity against tumor cells.
- Brand names
- Paraplatin + GemzarParaplatin + Infugem
- Other names
- GemCarbo
02
Targets
DNADNA polymerase familyRNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on gemcitabine + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + carboplatin.